US removes Israel from intellectual property watch list

As result of patent laws, mostly having to do with pharmaceuticals, Israel was on list that subjects countries to increased scrutiny on trade.

March 2, 2014 17:32
1 minute read.
Inside Teva

Inside Teva. (photo credit: REUTERS/Ronen Zvulun)


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analysis from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief


The Office of the United States Trade Representative on Friday removed Israel from an intellectual property watch list it has been on since 2005.

For almost a decade, Israel was included on the Special 301 Report Watch List as a result of patent laws, mostly having to do with pharmaceuticals.

Teva, the largest company listed on the Tel Aviv Stock Exchange, is the world’s biggest manufacturer of generic drugs.

Inclusion on the list subjects countries to increased scrutiny on relevant trade issues, and even possible sanctions.

Economy Minister Naftali Bennett called the decision an “important vote of confidence by the US,” saying the move would help Israel advance its industry and innovation, not just in the US but around the world.

Justice Minister Tzipi Livni vowed to continue strengthening Israeli intellectual property rights.

“This is a significant achievement, which reflects great efforts for advancing the international status and position of Israel as a leading country in intellectual property,” she said.

In 2008, the two countries began negotiations over how to move forward, and in 2010 they signed a memorandum of understanding outlining steps Israel could take to satisfy US concerns.

Progress led the Office of the US Trade Representative to move Israel from its priority watch list to its regular watch list in 2012. Friday’s announcement indicated an assessment on the US’s part that Israel had fulfilled its obligations, passing several laws in accordance with the understanding.

In particular, it advanced the last of three pieces of legislation in the Knesset to protect “pharmaceutical test data and patent term extension, and to publish patent applications promptly after the expiration of a period of 18 months from the time an application is filed.”

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection


Cookie Settings